Euro Pacific Asset Management LLC Decreases Stock Position in Novo Nordisk A/S (NYSE:NVO)

Euro Pacific Asset Management LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 91,390 shares of the company’s stock after selling 2,820 shares during the quarter. Novo Nordisk A/S accounts for approximately 1.7% of Euro Pacific Asset Management LLC’s investment portfolio, making the stock its 23rd largest position. Euro Pacific Asset Management LLC’s holdings in Novo Nordisk A/S were worth $7,985,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. Natixis Advisors LLC raised its position in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after purchasing an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 45.3% during the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares during the last quarter. Versant Capital Management Inc purchased a new position in Novo Nordisk A/S during the 4th quarter valued at $86,000. Talbot Financial LLC bought a new position in Novo Nordisk A/S in the 4th quarter valued at $4,066,000. Finally, Zions Bancorporation N.A. lifted its position in shares of Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after purchasing an additional 6,726 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Up 8.4 %

NYSE:NVO opened at $87.94 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company has a market cap of $394.65 billion, a PE ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. The company’s 50 day moving average is $95.62 and its two-hundred day moving average is $115.55.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.